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ABSTRACT 12 
Background: While partial nephrectomy (PN) represents the standard surgical management 13 
for cT1 renal masses, its role for cT2 tumors is controversial. Robotic assisted PN is being 14 
increasingly implemented worldwide.  15 
Objective: To analyze perioperative, functional, oncological outcomes of robot-assisted PN 16 
(RAPN) for cT2 tumors. 17 
Design, setting, and participants: Retrospective analysis of a large multicenter multi-18 
national dataset of patients with non-metastatic cT2 masses treated with robotic surgery 19 
(ROSULA: RObotic SUrgery for LArge renal mass).  20 
Intervention: Robotic assisted PN (RAPN). 21 
Outcome measurements and statistical analysis: Patients’ demographics, lesion 22 
characteristics, perioperative variables, renal functional data, pathology and oncological data 23 
were analyzed. Univariable and multivariable regression analyses assessed the relationships 24 
with the risk of intra-/post-operative complications, recurrence and survival. 25 
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Results and limitations: 298 patients were analyzed. Median tumor size was 7.6 cm (7-8.5). 1 
Median RENAL score was 9 (8-10). Median ischemia time was 25 min (20-32). Median 2 
estimated blood loss was 150 ml (100-300). Sixteen patients had intraoperative 3 
complications (5.4%), whereas 66 (22.1%) had postoperative complications (5.0% were 4 
Clavien grade >3). Multivariable analysis revealed that lower RENAL score (OR 0.46, 5 
p=0.021) and confirmed pathological pT2 stage (OR 0.51, p=0.001) were protective against 6 
postoperative complications. 243 lesions (81.6%) were malignant. Twenty patients (8.2%) 7 
had positive surgical margins. Ten deaths and 25 recurrences/metastases occurred at a 8 
median follow-up of 12 months (5-35). At univariable analysis, higher pT stage was 9 
predictive of likelihood of recurrences/metastases (p=0.05). ANOVA test showed significant 10 
deterioration of renal function at discharge, while remaining stable over time at 1-yr follow-11 
up. Main limitation of this study is the retrospective design. 12 
Conclusions: RAPN in setting of select cT2 renal masses can be safely performed with 13 
acceptable outcomes. Further studies are warranted to corroborate our findings and to better 14 
define the role of robotic nephron-sparing for this challenging indication. 15 
 16 
Patient summary: This report shows that robotic surgery can be used for safe removal of a 17 
large renal tumor in a minimally invasive fashion, maximizing preservation of renal function, 18 








1. Introduction 1 
Current guidelines recommend partial nephrectomy (PN) as the standard surgical 2 
treatment for clinical T1a renal tumors, whenever technically feasible [1, 2], given better 3 
renal functional preservation compared to radical nephrectomy (RN) [3]. However, for larger 4 
localized renal tumors, RN is still regarded as the reference standard, despite emerging data 5 
suggesting a potential role for a nephron-sparing approach in selected cases [4]. For T1b 6 
renal masses, PN was shown to provide to be not inferior to RN in terms of cancer control [5-7 
7]. Recent reports, mainly limited to open surgery series, suggest that even in patients with 8 
larger masses (> 7 cm, clinical T2), PN does not compromise cancer-specific mortality [8–9 
10].  10 
With the diffusion of robotic daVinci surgery, experience with robot-assisted PN 11 
(RAPN) has exponentially grown over the last decade, and this has led to broaden the 12 
utilization of the procedure to more complex tumors. However, RAPN for clinical T2 renal 13 
masses represents a challenging intervention, and very few case series have been reported to 14 
date [11-16].  15 
The aim of the present study was to analyze the perioperative, functional and 16 
oncological outcomes of RAPN for cT2 tumors in a large multi-institutional dataset (RObotic 17 
SUrgery for LArge renal mass – ROSULA project). 18 
 19 
2. Materials and Methods 20 
2.1. Study design 21 
The ROSULA is a multi-center multi-national project including 22 robotic centers 22 
worldwide. A dataset of patients consecutively underwent robotic surgery either by radical or 23 
nephron sparing approach for > cT2 renal masses was created. Institutional Review Board 24 
5 
 
approval or exempt was obtained at each Center. The purpose-built ROSULA database was 1 
queried for patients with non-metastatic cT2 renal masses who had undergone RAPN at 19 of 2 
participating institutions during the study period (July 2007 – Sep 2017) (Suppl. Figure 1).  3 
The following parameters were collected:  4 
a. patients’ baseline characteristics (age, gender, race, body mass index [BMI], 5 
ASA score, presence of diabetes mellitus, hypertension or preoperative 6 
chronic kidney disease [CKD] stage > III, solitary kidney status, preoperative 7 
hemoglobin, serum creatinine and estimated Glomerular Filtration Rate, as 8 
calculated by the MDRD formula [17];  9 
b. tumor characteristics (side, clinical size, clinical stage according to TNM [18], 10 
cystic features, RENAL nephrometry score (tumor complexity was graded as 11 
low, moderate and high, RENAL score 4–6, 6–9 and 10–12, respectively 12 
[19]);  13 
c. perioperative variables (transperitoneal vs retroperitoneal approach, operative 14 
time, warm ischemia time, percentage of clamp-less and cold ischemia 15 
technique procedures, estimated blood loss [EBL], intra-operative 16 
complications [including transfusions], conversions, and postoperative 17 
complications [graded according to the Clavien-Dindo system [20] – 18 
complications > grade III were considered as major], length of hospital stay 19 
and hemoglobin at discharge;  20 
d. pathology data (pathologic tumor size, pathologic stage according to TNM, 21 
tumor histology according to the 2004 World Health Organization criteria 22 
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[21], tumor grade according to Fuhrman [22], margin status, presence of 1 
sarcomatoid differentiation, presence of tumor thrombus).  2 
e. Functional data, including serum creatinine and eGFR at discharge and at 1, 6 3 
and 12 postoperative months. Postoperative “early” (at discharge) acute renal 4 
injury (AKI) was defined according to the RIFLE (Risk of renal dysfunction, 5 
Injury to the kidney, Failure of kidney function, Loss of kidney function and 6 
End-stage kidney disease) criteria [23]. 7 
f. Oncological data, including tumor recurrence, tumor metastasis, cancer-8 
specific mortality.  9 
 10 
2.2. Study objectives 11 
Primary study endpoint was the assessment of surgical (perioperative) outcomes. In 12 
this regard, as a surrogate of surgical quality, a “trifecta” outcome was used, which included 13 
negative surgical margins, no perioperative complications, and WIT < 25 minutes [24]. 14 
Secondary endpoints were the short term (1 year) functional and oncological outcomes. 15 
  16 
2.3. Statistical analysis 17 
Means + standard deviations (SD) were used to report variables with a normal 18 
distribution; medians and interquartile ranges (IQR) in case of variables with a non-normal 19 
distribution instead. Frequencies and proportions were used to report categorical variables. 20 
The means of continuous and categorical variables were compared by using the student T- 21 
and the Chi-square tests, respectively. ANOVA test was used to compare more than two 22 
groups.  23 
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Univariable and multivariable forward stepwise logistic regression analyses assessed 1 
the relationships of variables of interest with the risk of: (a) intraoperative complications, (b) 2 
overall postoperative complications, and (c) postoperative renal dysfunction as defined 3 
according to the RIFLE criteria. 4 
Univariable analyses were used to test the effect of variables of interest on the 5 
probability of recurrences or metastases. Due to the small number of cancer-related deaths, 6 
the analysis was avoided for this outcome. Significance level was set at p-value < 0.05. 7 
Statistical analysis was performed using Statistic 8.0 Software (Tulsa, Oklahoma, US). 8 
 9 
3. Results 10 
Two-hundred ninety-eight patients who underwent RAPN for cT2 renal mass were 11 
included in the analysis. In supplementary Table 1, number of cases per Institution is 12 
provided. A trend towards a higher number of cases was observed during the study period 13 
(Figure 1). Patients’ baseline characteristics are reported in Table 1. Median clinical tumor 14 
size was 7.6 (IQR: 7-8.5) cm. Median RENAL score was 9 (IQR: 8-10).  15 
 16 
3.1. Surgical outcomes 17 
Only 8.4% of the procedures were performed by retroperitoneal approach. Mean 18 
operative time was 163 + 75 minutes. Twenty-two (7.4%) procedures were performed by 19 
clamp-less approach. Median ischemia time was 25 (IQR: 20-32) minutes, with 5% of 20 
procedures performed by cold ischemia technique. Median estimated blood loss (EBL) was 21 
150 ml (100-300). Sixteen patients had intraoperative complications (5.4%). Fifteen patients 22 
received intraoperative blood transfusions (5%), and one conversion to RN occurred (0.3%), 23 
which was due to sticky fat possibly compromising the oncological efficacy in soft large 24 
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mass with high risk of rupture. The detailed list of perioperative data and complications is 1 
reported in Table 2. Sixty-two patients (20.8%) had postoperative complications. Among 2 
these, fifteen had a major (Clavien grade >3) complication (5%).  3 
Median length of hospitalization was 4 days (3-5). At discharge, hemoglobin was 4 
significantly reduced with respect to baseline (13.8+1.7 vs 10.4+3.0; p<0.001). 5 
At univariable analysis, EBL and BMI were predictors of intraoperative 6 
complications (p < 0.001 and = 0.001, respectively). Clinical tumor size (< 0.001) and pT 7 
stage 3 vs 2 (p = 0.003) were predictors of postoperative complications. Multivariable 8 
logistic regression demonstrated that simple RENAL score (4-6) and non-pathological 9 
upstaging (pT2) were independently associated with a decreased risk of development of 10 
complications (OR 0.46, p=0.021 and OR 0.51, p=0.001, respectively).  11 
3.2. Renal functional outcomes 12 
ANOVA test showed significant deterioration of renal function at discharge (median 13 
decrease 17.5%, p-values < 0.001), while at 1-yr follow-up both SCr and eGFR were 14 
comparable to their discharge value (p = 0.798 and 0.159, respectively) (Supplementary 15 
Figure 2). Out of 180 patients who had complete eGFR data preoperatively and at discharge, 16 
sixty-two patients (34.4%) experienced postoperative AKI (Table 2). On multivariate 17 
analysis, preoperative eGFR < 60 ml/min/1.73m2, increasing clinical tumor size (every 1 cm), 18 
and preoperative diabetes mellitus were independent predictors of postoperative AKI (OR = 19 
2.61, 1.98 and 5.13, p < 0.001, = 0.009 and 0.018, respectively - Table 3). 20 
3.3. Oncological outcomes 21 
Pathology data are detailed in Table 4. Median size at final pathology was 7.4 cm 22 
(IQR 6.4-8.2). Most of the lesions were malignant (n=243; 81.6%). Among malignant 23 
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lesions, 58 % were Fuhrman grade 1-2 (or without grading), and 42% Fuhrman grade 3-4. In 1 
9 cases a sarcomatoid differentiation was found. Twenty patients (8.2%) had positive 2 
surgical margins. Forty-two patients (17.2%) were down-staged to pT1a-b, whereas 93 3 
(38.3%) were upstaged to pT3-4 at final pathology. Among the 63 patients who underwent 4 
lymph-nodes dissection, only one patient had nodal involvement (pN1). 5 
Twenty-five recurrences or progression to metastasis (actuarial progression rate: 6 
10.3%) were observed and 2 deaths (0.7%) related to metastatic renal cancer occurred after a 7 
median follow-up of 12 months.  8 
At univariable Cox regression, pT3a pathological upstaging was the only significant 9 
predictor of recurrence/metastasis (p = 0.05, Figure 2A); tumor thrombus, higher Fuhrman 10 
grade (3-4) and sarcomatoid differentiation showed a trend towards significance (Figure 2B 11 
and Figure 3A, B, respectively). 12 
 13 
3.4. Trifecta 14 
A “trifecta” outcome was achieved in 120 (49.4%) patients among the 243 patients 15 
who had malignant lesions. 16 
 17 
4. Discussion 18 
To the best of our knowledge, this represents the largest series of RAPN for cT2 renal 19 
masses to date. The present analysis relies on a robust sample from various Institutions 20 
worldwide with an established robotic program, and it allows to draw some interesting 21 
conclusions about this “extreme” indication for a robotic nephron-sparing approach. Overall, 22 
we found RAPN for cT2 renal masses to be safely feasible, with acceptable perioperative and 23 
functional outcomes.  24 
10 
 
In a recent systematic review, Mir et al found only 4 studies comparing PN to the 1 
“gold standard” RN in the subset of patients with cT2 tumors. In their analysis, PN was 2 
found to have significantly higher blood losses and likelihood of complication rates. 3 
Nonetheless, these PN in these comparative analyses were performed with open and 4 
laparoscopic, as opposed to robotic approach. [4].  5 
Studies on robotic nephron-sparing surgery for larger masses remain quite sparse and 6 
limited [11-14]. Malkoc et al. recently reported a single center study comparing a series of 54 7 
robotic to 56 open partial nephrectomies for >7 cm renal tumors [15]. RAPN was found to be 8 
superior to the open approach, but median ischemia time was above 30 minutes in both the 9 
approaches. The incidence of overall complications was 18.5 % and 28.6 %, in favor of 10 
robotic, with a major complications rate of 3.7 % and 12.5 %, respectively. Complications 11 
rate of RAPN for highly complex renal masses were reported to be almost the same in a 12 
recent prospective series by Porpiglia et al., with 23.8% and 4.8 of overall and major 13 
complications, respectively [25]. 14 
 Of note, the results from our multicenter study confirmed that even in case of cT2 15 
renal tumors, the robotic approach allows for acceptable ischemia time (median 25 min) [26], 16 
and complication rates (21% overall, 5% major complications). If data on complications are 17 
slightly higher than what previously reported for RAPN [11-16], they appear to be 18 
consistently lower to series reporting complications for T2 open PN [6, 15]. Our findings that 19 
increasing tumor complexity and tumor size are predictive of postoperative complications are 20 
consistent with recent reports from large national and institutional databases. [27, 28]. Our 21 
reported Trifecta rate of 49.4% is lower than reports from series with small renal masses. 22 
Nonetheless, given that predictors for Trifecta include increasing tumor complexity or size, 23 
11 
 
our findings are not surprising. Interestingly, our findings are similar to those of Abdel 1 
Raheem and co-workers published who reported a Trifecta rate of 37.5% when examining 2 
Trifecta rates in patients undergoing PN for complex renal masses [29].  3 
Regarding the functional data, one-third of the patients experienced postoperative 4 
AKI, as assessed by RIFLE criteria [23]. Similar rates were reported in a large sample of PN 5 
procedures by Rajan et al [30]. AKI was found to correlate by baseline patient’s factors like 6 
eGFR and diabetes, as also reported by others [31]. More interestingly, tumor size was also a 7 
predictor of postoperative AKI, which can be explained by larger excision of renal 8 
parenchyma. In this respect, Zhang et al reported that parenchymal mass reduction and 9 
ischemia both contribute to acute changes after PN, and while postoperative AKI is 10 
associated with suboptimal recovery, even patients with grade 2/3 AKI up to 90% of 11 
recovery can be expected [32]. In our analysis, while eGFR was found overall to be 12 
significantly reduced at 1 month postoperatively more than 15%, it remained stable over 13 
time, which is in line with previous findings [33]. 14 
Notably, a significant proportion of patients experienced up-staging to pT3a after PN. 15 
Up-staged pT3a patients had worsened recurrence/metastasis free survival across all clinical 16 
tumor stages after PN. In a recent single institution analysis, Mouracade and colleagues 17 
evaluated on more than 1000 patients with cT1 staged renal masses the perioperative 18 
morbidity, oncological outcome and predictors of pT3a upstaging after partial nephrectomy 19 
[34]. They found that male gender and R.E.N.A.L. score were preoperative predictors of 20 
upstaging. In our multicenter cohort, we had 70% of male patients and a median RENAL 21 
score of 9. In our study, while we noted several factors trending towards significance as 22 
12 
 
predictors for recurrence or metastases, none reached statistical significance. This is most 1 
likely a limitation due to the short follow up of our cohort.  2 
While the adoption of a nephron sparing approach for higher risk masses might be 3 
concerning from an oncological standpoint, population-based studies suggest that even in 4 
patients with adverse pathologic features, PN does not seem to compromise cancer-specific 5 
mortality, and therefore the decision to perform a PN should mostly rely on the technical 6 
feasibility [35]. In our series, the high pT3 staged tumors (33%) might be one explanation for 7 
the 8% rate of positive surgical margins. Indeed, 10 patients (50%) who had positive surgical 8 
margins were upstaged to pT3. Moreover, if one considers the open surgery literature 9 
specifically regarding the larger masses, this rate compares favorably. Indeed, in a recent 10 
review the range of positive surgical margins for these cases was found to be 0 to 31% [36]. 11 
In support of our data, in the Mouracade study pT3a tumors had 18.6% of positive surgical 12 
margins rate [34].  Using the US National Cancer Database, Fero et al. reported an overall 13 
increased rate of positive margins at 7.3%, driven by increasing use of minimally invasive 14 
approaches, and not by higher clinical stage [37].  15 
Moreover, in a multicenter retrospective survey, Bensalah and co-authors analyzed 16 
111 patients with PSM, concluding that PSM status more likely occurs when surgery is 17 
imperative, as could be the case of more complex renal lesions. In that study, PSM status did 18 
not influence cancer-specific survival but it was associated with increased risk of recurrence 19 
[38]. More recently, Khalifeh and colleagues found an 18-fold higher risk for recurrence in 20 
case of PSM, after adjusting for multiple tumors, tumor size, tumor growth pattern and 21 
pathological stage [39].  22 
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Concerning the oncological outcomes, our analysis showed an actuarial rate of 8.6% 1 
of recurrences or metastases, with 2 cancer-related deaths (0.7% actuarial cancer-specific 2 
mortality) occurred after a median follow-up of 12 months. Such findings could be read as 3 
satisfactory too. Indeed, even if there is still limited retrospective evidence about the 4 
oncological efficacy of PN for renal tumors larger than 7 cm, the available literature data 5 
reported in a recent review with follow-up range of 13.1 to 70 months showed 5-year 6 
progression-free survival and 5-year overall survival ranging from 71 to 92.5% and from 66 7 
to 94.5%, respectively [36].  8 
Our study is not devoid of limitations. First and foremost, the retrospective design 9 
accounts for some inherent biases, including patient selection and differences in surgical 10 
technique. It was beyond the scope of the present analysis to compare RAPN to the reference 11 
standard RN, and therefore a control arm was not considered. Also, the available follow-up 12 
of this cohort was limited (median 12 months), and it did not allow evaluating long term 13 
outcomes. One might argue that would be interesting to know how many cT2 renal masses 14 
were seen at these institutions during the time-period of the study to gauge the level of 15 
selection bias and to determine if most patients with cT2 masses offered robotic PN and how 16 
patients were ultimately selected for a robotic vs open partial approach. Unfortunately, we do 17 
not have this detailed information. The choice of one approach (robotic) versus the other 18 
(open) was at discretion of each surgeon. Having said that, the aim of the study was not to 19 
determine “practice patterns” of management of these large renal masses at participating 20 
institutions, but rather to report their experience with the robotic PN for this “extreme” 21 
indication. Concerning the evaluation of renal function, we concur that while the use of 22 
eGFR is a practical viable option, ideally a nuclear renal scan should be adopted [17]. 23 
14 
 
However, this was not available for this study. Last, no centralized radiologic or pathologic 1 
review was performed for the here reported cases. 2 
Notwithstanding these limitations, this series represents the largest describing the 3 
outcomes of mostly elective RAPN for large (clinical stage T2) renal masses in a “real-life” 4 
scenario. On the other hand, these study findings may not be generalizable to the entire 5 
urologic community, and they are reserved for experienced robotic surgeons/centers of 6 
excellence. Even though cT1a and certainly cT1b tumors may be challenging for most, and 7 
PN remains overall underused for these “standard” indications. Future definition of 8 
maximum tumor threshold and more accurate preoperative staging are mandatory to optimize 9 
the outcomes. Moreover, image-guidance technology could aid in expanding the role of 10 
RAPN for these challenging indications [40].  11 
 12 
Conclusions 13 
RAPN in case of large renal masses can be safely performed with acceptable 14 
outcomes. Further studies are warranted to corroborate our findings and to better define the 15 
role of RAPN for this challenging indication. For the time being, the decision to proceed with 16 
robotic nephron sparing surgery should be weighted based on the technical feasibility and 17 
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Figures’ Legend 1 
Figure 1. Chart showing the number of robot assisted partial nephrectomy (RAPN) during the 2 
study period. 3 
Figure 2. Cumulative Proportion of Recurrence or metastasis (Kaplan-Meier curves) after 4 
stratification by A) pT stages according to TNM and B) presence of tumor thrombus (TT). 5 
Figure 3. Cumulative Proportion of Recurrence or metastasis (Kaplan-Meier curves) after 6 
stratification by A) Fuhrman grade and B) presence of sarcomatoid pattern (sarc.). 7 
 8 
Supplementary Figure 1. Study flow chart. 9 
Supplementary Figure 2. Box and Whisker Plots showing Median, Inter-Quartile range (25-10 
75%) and Minimum and Maximum values of the distribution (Min-Max) of A) Serum Creatinine 11 
(SCr) and B) estimated Glomerular Filtration Rate (eGFR). Overall ANOVA test showed a 12 
significant difference in SCr and eGFR (preoperative vs. postoperative, p < 0.001). Conversely, 13 
no differences were found among the postoperative values of both SCr and eGFR (p = 0.798 and 14 
0.159, respectively).  15 
 16 
 17 
 18 
 19 
